Navigation Links
Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
Date:8/29/2012

sosei.com">http://www.sosei.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

References

  1. ClinicalTrials.gov. Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK). NCT01120691. http://www.clinicaltrials.gov/ct2/show/NCT01120691?term=NCT01120691.&rank=1. Last accessed 21 August 2012.
  2. ClinicalTrials.gov. QVA149 versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ILLUMINATE). NCT01315249 http://www.clinicaltrials.gov/ct2/show/NCT01315249?term=NCT01315249&rank=1. Last acc
    '/>"/>

SOURCE Sosei Group Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sosei Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
4. BioNeutral Group Receives $400,000 in Equity Financing
5. MiMedx Group Completes $5,000,000 Private Placement
6. Use Biomarkers in Alzheimers Disease Clinical Trials, Says Expert Group
7. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
8. Lend Lease Announces the Appointment of Tom Chapman as Director Operations for the Life Sciences Group in the Atlantic Region
9. Statewide Network of Angel Investor Groups Announced in Alabama
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on Wednesday, March 7, 2012
11. Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
(Date:2/27/2015)... February 27, 2015 Cytokinetics, Incorporated (Nasdaq: ... February 28 with patients and health care advocates in ... Rare Disease Day®. Rare Disease Day is dedicated ... attention to the special challenges faced by patients with ... “Cytokinetics is proud to stand alongside patients and caregivers ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... The U.S. Food and Drug,Administration (FDA) has ... treatment for complicated intra-abdominal and complicated urinary,tract ... a wide range of Gram-positive(1) and Gram-negative(2),bacteria ... serious infections. DORIBAX belongs to a ...
... 15 Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ... today at the 63rd Annual Meeting of the ... who received 100 mg/day or,150 mg/day of desvenlafaxine, ... significant reduction in moderate to severe,vasomotor symptoms (VMS) ...
... Telik, Inc.,(Nasdaq: TELK ) announced that ... the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical ... TELCYTA data by,the agency and permits the resumption ... Palo Alto, CA is a biopharmaceutical company focused ...
Cached Biology Technology:FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 2FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 3FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 4FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 5Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5FDA Removes Partial Hold on TELCYTA Clinical Development 2
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... , Europe,s ... European Patent Office to present a video retrospective of the most ... featured: Christofer Toumazou and Sophie Wilson   ... of the Award   Starting on 22 January 2015 ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... easier to find things claiming to be sustainable than it ... University geographer is trying to pin down exactly what sustainability ... it. Her goal is to better understand what is important ... sustain with the hope that this will later help civic ...
... St. Joseph, Michigan A new internet-based tool for ... involved and to optimize design by allowing rapid development ... issue of Resource: Engineering & Technology for a ... Biological and Agricultural Engineering at the University of Missouri, ...
... Osteoporosis Foundation (IOF) today shows that osteoporosis is a serious ... 14 Asian countries, regions or territories, ,The Asian Audit, is ... countries as well as collectively across the region. The report,s ... is predicted for Asia as a whole , Already hip ...
Cached Biology News:K-State geographer working to clarify what sustainability really means to rural decision-makers 2Web-based innovation improves, eases agricultural terrace design 2New report shows rising tide of fractures in Asia 2New report shows rising tide of fractures in Asia 3
... is obtained from non-demolished blood ... fasted donors. The donors are ... and are maintained on an ... Protein Concentration : 85 mg/ml ...
... Captiva 96-well Filter Plates are offered ... and 0.45 um depth filter plates are ... LC/MS analysis. Filtration is simple, versatile, and ... columns. The Captiva 10 um glass fiber ...
... CyScribe First-Strand cDNA Labeling System ... Kit, 50 reactions. For the generation ... cDNA.Optimized reagents are packaged together for ... optimized protocols can be used for ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
Biology Products: